Although the loss-of-function hypothesis is valid and plausible, recent results from clinical trials suggest that therapeutic approaches that overexpress wild type GCase or try to correct its folding may not be completely suitable for PD patients, particularly since GBA1 mutations in PD patients are heterozygous (reviewed in [17]). This evidence concerns the gene GBA1 and Parkinson disease.